Pscilly

Compass Pathways sends psilocybin treatment application to FDA

By · Published · Updated

Compass Pathways announced on November 9 that it had completed submitting a New Drug Application to the US Food and Drug Administration for COMP360, its investigational synthetic psilocybin formulation for treatment-resistant depression. The treatment is not yet approved; the company says any launch would depend on FDA approval. If approved, it would be the first classic psychedelic medicine approved by the agency, according to the announcement. The application includes findings from the company’s two phase 3 trials, COMP005 and COMP006, which together involved more than 1,000 participants. In COMP006, participants’ current depressive episodes had lasted an average of more than three years, and they had experienced an average of more than six depressive episodes over their lifetimes. The company reported that 39% of participants who received a 25-milligram dose had at least a 25% reduction in MADRS scores by week six after two fixed doses, with response maintained through at least week 26. Compass compared that result with a 25% response in COMP005 after a single dose. The report says the findings support the potential value of a second dose for some participants. Psychiatrist Gus Alva, an investigator in both trials, said the responses he observed involved psychotherapy and supervision by trained therapists. The FDA awarded COMP360 a National Priority Voucher, which the company says sets a review target of one to two months. Compass expects a possible launch in the first half of 2027, subject to approval. For mushroom readers, the milestone reflects growing clinical research into a compound associated with psychedelic mushrooms, while the application remains under regulatory review.

Published
November 9, 2026
Source
psychiatrictimes.com